Literature DB >> 23482734

Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy.

Julie Doan1, Hubert Zakrzewski-Jakubiak, Julie Roy, Jacques Turgeon, Cara Tannenbaum.   

Abstract

BACKGROUND: As rates of polypharmacy rise and medication regimens become more complex, the risk of potential cytochrome P450 (CYP)-mediated drug-drug interactions (DDIs) is a growing clinical concern for older adults.
OBJECTIVE: To determine the prevalence of potential CYP-mediated DDIs in older hospitalized adults with polypharmacy and analyze the relationship between the number of drugs dispensed and the probability of these interactions in this high-risk population.
METHODS: A prospective 16-week cohort study was conducted among consecutive new patients aged 65 years and older with polypharmacy (>5 drugs) admitted to a community hospital. The medication profiles of these patients were analyzed with a new multidrug cytochrome-specific software program. The prevalence of potential CYP-mediated DDIs was determined, with the probability calculated as a function of the number of medications dispensed using multivariate Poisson regression adjusted for age and sex. Comparative performance of the software program and a standard 2-drug alert program for detecting these DDIs was evaluated using the Wilcoxon-Mann-Whitney rank-sum test. Pharmacists' decisions to recommend medication adjustment based on the probability of CYP-mediated DDIs were recorded.
RESULTS: The prevalence of potential CYP-mediated DDIs detected among 275 older adults with polypharmacy was 80%. The probability of at least 1 CYP-mediated DDI was 50% for persons taking 5-9 drugs, 81% with 10-14 drugs, 92% with 15-19 drugs, and 100% with 20 or more drugs. Addition of each medication to a 5-drug regimen conferred a 12% increased risk of a potential CYP-mediated DDI after adjustment for age and sex (OR 1.12; 95% CI 1.09-1.14). The multidrug software identified a median increase of 3 (95% CI 2.5-3.5) potential CYP-mediated DDIs per patient, compared to use of the standard 2-drug alert software. Pharmacists targeted patients for medication adjustment or close clinical monitoring in 23% of cases.
CONCLUSIONS: The prevalence of potential CYP-mediated DDIs is high in geriatric patients with polypharmacy. The risk of DDIs increases as a function of the number of medications dispensed. Pharmacists' decision to intervene for potential CYP-mediated DDIs depends on clinical judgment in addition to the output from drug alert software programs, but may be facilitated by a single multicomponent, multidrug potential CYP-mediated DDI assessment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23482734     DOI: 10.1345/aph.1R621

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  47 in total

Review 1.  Routine deprescribing of chronic medications to combat polypharmacy.

Authors:  Doron Garfinkel; Birkan Ilhan; Gulistan Bahat
Journal:  Ther Adv Drug Saf       Date:  2015-12

Review 2.  Prevalence of statin-drug interactions in older people: a systematic review.

Authors:  Michele Thai; Emily Reeve; Sarah N Hilmer; Katie Qi; Sallie-Anne Pearson; Danijela Gnjidic
Journal:  Eur J Clin Pharmacol       Date:  2016-01-20       Impact factor: 2.953

Review 3.  Predicting risk of adverse drug reactions in older adults.

Authors:  Amanda Hanora Lavan; Paul Gallagher
Journal:  Ther Adv Drug Saf       Date:  2016-02

4.  Coadministration of co-trimoxazole with sulfonylureas: hypoglycemia events and pattern of use.

Authors:  Alai Tan; Holly M Holmes; Yong-Fang Kuo; Mukaila A Raji; James S Goodwin
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2014-05-24       Impact factor: 6.053

5.  The effect of polypharmacy on prefrontal cortex activation during single and dual task walking in community dwelling older adults.

Authors:  Claudene J George; Joe Verghese; Meltem Izzetoglu; Cuiling Wang; Roee Holtzer
Journal:  Pharmacol Res       Date:  2018-11-05       Impact factor: 7.658

6.  Educational needs, practice patterns and quality indicators to improve geriatric pharmacy care.

Authors:  Dan Zou; Cara Tannenbaum
Journal:  Can Pharm J (Ott)       Date:  2014-03

7.  The Impact of Provider Networks on the Co-Prescriptions of Interacting Drugs: A Claims-Based Analysis.

Authors:  Mei-Sing Ong; Karen L Olson; Laura Chadwick; Chunfu Liu; Kenneth D Mandl
Journal:  Drug Saf       Date:  2017-03       Impact factor: 5.606

8.  Cytochrome P450 interactions are common and consequential in Massachusetts hospital discharges.

Authors:  T H McCoy; V M Castro; A Cagan; L Snapper; A Roberson; R H Perlis
Journal:  Pharmacogenomics J       Date:  2017-07-11       Impact factor: 3.550

Review 9.  Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes.

Authors:  Kasia J Lipska; Harlan Krumholz; Tacara Soones; Sei J Lee
Journal:  JAMA       Date:  2016-03-08       Impact factor: 56.272

10.  Motoric Cognitive Risk Syndrome in Polypharmacy.

Authors:  Claudene J George; Joe Verghese
Journal:  J Am Geriatr Soc       Date:  2020-02-24       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.